Unmet Clinical Needs in Relapsed/Refractory Marginal Zone Lymphoma

Panelists discuss how despite progress, significant unmet needs remain for patients with relapsed or refractory marginal zone lymphoma. Many individuals experience repeated relapses, limited treatment durability, or cumulative adverse effects from prior therapies. Addressing these challenges requires continued research and access to novel, less toxic options that provide lasting control and improved quality of life.

Early diagnosis and effective sequencing are key to improving outcomes. Better understanding of molecular subtypes may allow clinicians to predict which patients will respond best to specific therapies. Supportive care, including mental health and symptom management, remains essential to ensure comprehensive treatment that values the whole person, not just the disease.

Advancing research and clinical collaboration are vital to closing these gaps. By prioritizing innovation and patient-centered care, the oncology community moves closer to achieving long-term remission for all individuals facing marginal zone lymphoma.